Diabetic retinopathy risk prediction in patients with type 2 diabetes mellitus using a nomogram model

Qian Wang1†, Ni Zeng2†, Hongbo Tang3, Xiaoxia Yang4, Qu Yao5, Lin Zhang1, Han Zhang5, Ying Zhang1, Xiaomei Nie6, Xin Liao1* and Feng Jiang7*

1Department of Endocrinology, Affiliated Hospital of Zunyi Medical University, Zunyi, China, 2Department of Dermatology, Affiliated Hospital of Zunyi Medical University, Zunyi, China, 3Department of Critical Care Medicine, The Third Affiliated Hospital of Zunyi Medical University (The First People’s Hospital of Zunyi), Zunyi, China, 4Department of Integrated (Geriatric) Ward, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China, 5Department of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, China, 6Department of Ophthalmology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China, 7Department of Neonatology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China

Background: This study aims to develop a diabetic retinopathy (DR) hazard nomogram for a Chinese population of patients with type 2 diabetes mellitus (T2DM).

Methods: We constructed a nomogram model by including data from 213 patients with T2DM between January 2019 and May 2021 in the Affiliated Hospital of Zunyi Medical University. We used basic statistics and biochemical indicator tests to assess the risk of DR in patients with T2DM. The patient data were used to evaluate the DR risk using R software and a least absolute shrinkage and selection operator (LASSO) predictive model. Using multivariable Cox regression, we examined the risk factors of DR to reduce the LASSO penalty. The validation model, decision curve analysis, and C-index were tested on the calibration plot. The bootstrapping methodology was used to internally validate the accuracy of the nomogram.

Results: The LASSO algorithm identified the following eight predictive variables from the 16 independent variables: disease duration, body mass index (BMI), fasting blood glucose (FPG), glycated hemoglobin (HbA1c), homeostatic model...
assessment-insulin resistance (HOMA-IR), triglyceride (TG), total cholesterol (TC), and vitamin D (VitD)-T3. The C-index was 0.848 (95% CI: 0.798–0.898), indicating the accuracy of the model. In the interval validation, high scores (0.816) are possible from an analysis of a DR nomogram’s decision curve to predict DR.

Conclusion: We developed a non-parametric technique to predict the risk of DR based on disease duration, BMI, FPG, HbA1c, HOMA-IR, TG, TC, and VitD.

KEYWORDS
nomogram model, type 2 diabetes mellitus, diabetic retinopathy, risk, prediction

Introduction

Currently, diabetes mellitus (DM) is one of the fastest-growing chronic diseases worldwide. An epidemiological study conducted between 2015 and 2017 in 31 cities and provinces of China indicated that the prevalence of DM was 11.0% (1). According to the International Diabetes Federation, there were 463 million diabetic patients between 20 and 79 years in 2019 globally. This number is expected to reach 578 million by 2045 and 700 million by 2045 (2). High blood sugar is a crucial marker of DM that damages the body’s microvasculature. For instance, diabetic retinopathy (DR) is a type of microangiopathy caused by diabetes. It is becoming increasingly common, as the number of people with DM is rising. By 2030, the estimated number of non-proliferative DR and progressive DR would be 191 million and 56.3 million, respectively. Additionally, due to a lack of awareness and understanding of DR, it has become the leading cause of vision loss in adults aged 30–60 years, significantly affecting the quality of life and posing a health risk. DR is silent at its inception; hence, its early detection, prevention, and therapy are critical for lowering its effect on life and social resources.

Several factors influence the onset and progression of DR. Hyperglycemia, hypertension, dyslipidemia, obesity, smoking, anemia, a lack of health information, and poor treatment adherence are risk factors of DR that can be altered. Whereas ethnicity, family history or inheritance, diabetes onset age, type of diabetes, and diabetes duration are all constant risk factors (3). Previously, studies have built a predictive model for the risk of DR in patients with type 2 diabetes mellitus (T2DM); however, the independent variables were different in all studies (4–6). Thus, this study collected the independent variables that have not appeared in previous studies and aimed to develop a comprehensive model for predicting the risk of DR and the need for early intervention.

Methods

Patients

We included 213 inpatients and outpatients with T2DM at the Affiliated Hospital of Zunyi Medical University between January 2019 and May 2021. The clinical data were collected in Zunyi, Guizhou, a southwestern region of China; hence, the participants were all Han Chinese. All patients with diabetes satisfied the WHO diagnostic criteria, including a fasting plasma glucose level >126 mg/dl and/or an oral glucose level of 75 mg 2 h later. Blood glucose was >200 mg/dl (7). The exclusion criteria were as follows: 1) People with T1DM and other forms of diabetes, including Cushing syndrome; 2) Patients with diabetes with acute diabetic complications, such as ketoacidosis; 3) Pregnant and lactating women; 4) Patients who were unable to perform a fundus examination, such as those with severe refraction in eyes and myopia/hyperopia with a history of >3 days; 5) Patients with eye diseases, such as glaucoma and severe cataracts, that affect fundus observation; 6) Patients with any other disease that can cause fundus hemorrhage; 7) Patients who consumed drugs that affect lipid metabolism and vitamin D (VitD) in the last 6 months. All individuals with T2DM were screened using CR-PGi (Canon). The CR-PGi captured no-dilatation fundus photographs, which have better sensitivity and specificity for screening DR, and high-quality fundus photographs can screen out the most clinically significant DRs (8). Patients screened for suspected DR were then referred to the ophthalmology department and underwent no-dilatation fundus photography, fluorescein fundus angiography, and optical coherence tomography by the same ophthalmologist to verify the diagnosis of DR. Data on gender, age, disease duration, systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI), fasting blood glucose (FPG), glycated hemoglobin (HbA1c), homeostatic model assessment-insulin
resistance (HOMA-IR), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), VitD, and creatinine (Cr) were obtained for all individuals via medical records. HOMA-IR was used to assess insulin resistance \[\text{IR index} = \frac{\text{FPG} (\text{mmol/L}) \times \text{FINS} (\text{mU/L})}{22.5} \geq 2.8\] \((9, 10)\).

**Statistical analysis**

Using least absolute shrinkage and selection operator (LASSO) regression, we improved the stability of the model by fitting a generalized linear model and performing variable selection and complexity adjustment (regularization). It screens the statistically significant independent variables and calculates the dominance ratio [odds ratios (OR)], 95% confidence interval (CI), and P-value for each independent variable. Finally, we performed a multifactor logistic regression analysis on the statistically significant independent variables \((5)\). The proposed methodology was then built using heterogeneous logistic regression and properties of the cable regression model. Characteristics also included frequency or P-value with 95% CI. We decided to employ bidirectional statistically significant results to construct a predictive nomogram. A P-value <0.05 was considered statistically significant. To forecast the DR incidence, we constructed a prediction model with appropriate adjustments and graphical representations. The accuracy of the DR nomogram was evaluated using the C-index \((11, 12)\), which was validated through bootstrapping. Preference curve analysis was used to determine the predicted results using a copy based on the projected benefit at scene probabilities \((6)\).

**Results**

**Characteristics of the patients**

In total, 213 patients with T2DM, including 59.15% men and 40.85% women were included. The patients’ mean age was 55.25 ± 9.34 years (range 29–83 years). Based on the fundus examination, the patients were divided into two groups: non-DR (53.05%) and DR (46.95%). Table 1 illustrates the essential characteristics of patients, including the detailed information of 16 clinical indicators.

**Variables to be chosen**

We analyzed 16 independent variables using R software. Among these, eight statistically significant independent variables or lambda coefficients, namely, disease duration, BMI, FPG, HbA1c, HOMA-IR, TG, TC, and VitD, were screened using LASSO regression analysis (Figures 1A, B).

**Model development for diabetic retinopathy prediction**

Furthermore, disease duration, BMI, FPG, HbA1c, HOMA-IR, TG, TC, and VitD were examined using multivariate logistic regression analysis. The results of the Cox regression analysis were presented as forest plots (Figure 2). We obtained the following as the DR risk factors: Disease duration \((5 < 10, \text{OR} = 4.8636; \geq 10, \text{OR} = 11.8582)\), BMI \((24 < 28, \text{OR} = 1.5497; \geq 28, \text{OR} = 2.1602)\), FPG \((\geq 7.0, \text{OR} = 16.1295)\), HbA1c \((\geq 7.0, \text{OR} = 1.7667)\), HOMA-IR \((\geq 2.8, \text{OR} = 1.5562)\), TG \((\geq 1.7, \text{OR} = 1.4719)\), TC \((\geq 5.2, \text{OR} = 1.7174)\), and VitD \((15 < 30, \text{OR} = 0.4177; \geq 30, \text{OR} = 0.3997)\). Using the aforementioned independent predictors, we created a model and presented it using a nomogram (Figure 3). Finally, we created a dynamic web-based calculator (https://dxyjiang.shinyapps.io/DRprediction/) that calculates the total score from each patient’s clinical indicators for determining the risk of developing DR (Figure 4).

**Accuracy of the cohort diabetic retinopathy exposure nomogram**

The C-index for evaluating the occurrence of DR in patients with T2DM was 0.848 (95% CI: 0.798–0.898), demonstrating a high validity (Figure 5). Additionally, the result of the bootstrap verification was 0.816. These results indicate that the model has good prediction accuracy.

**Clinic application**

The DR nomogram was made up of scales for several variables to calculate the likelihood of a given result. According to the judgment curve, non-adherence use of the nomogram raises the projected chance of DR incidence if the thresholds of the patient and doctor are >2% and 85%, respectively. The overlaps were compiled in this study to ensure an equal net gain (Figure 6).

**Discussion**

Nomograms are simple, quick, cheap, and noninvasive techniques to monitor patients and make appropriate clinical treatment decisions \((13)\). They are used in various medical professions, such as for predicting tumor diagnostic outcomes and therapeutic effects. Nonetheless, only a few studies have attempted to forecast the risk of DR in patients with T2DM. Hence, this study gathered clinical data and demographic characteristics of patients with T2DM and constructed a new prediction model for determining the probability of acquiring DR.
### TABLE 1 Differences between demographic and clinical characteristics of the non-DR and DR groups.

| Demographic characteristics | Non-DR (n = 113) | DR (n = 100) | Total (N = 213) |
|-----------------------------|------------------|-------------|----------------|
| Age (years)                 |                  |             |                |
| <50                         | 4 (44.44)        | 5 (55.56)   | 9 (4.23)       |
| 50–70                       | 107 (55.15)      | 87 (44.85)  | 194 (91.08)    |
| >70                         | 2 (0.20)         | 8 (0.80)    | 10 (4.69)      |
| Gender                      |                  |             |                |
| Male                        | 68 (53.97)       | 58 (46.03)  | 126 (59.15)    |
| Female                      | 45 (51.72)       | 42 (48.28)  | 87 (40.85)     |
| Disease duration (years)    |                  |             |                |
| <5                          | 65 (76.47)       | 20 (23.53)  | 85 (39.91)     |
| 5 < 10                      | 46 (40.00)       | 69 (60.00)  | 115 (53.99)    |
| ≥10                         | 2 (15.38)        | 11 (84.62)  | 13 (6.10)      |
| BMI                         |                  |             |                |
| <24                         | 66 (72.53)       | 25 (27.47)  | 91 (42.72)     |
| 24 < 28                     | 37 (38.14)       | 60 (61.86)  | 97 (45.54)     |
| ≥28                         | 10 (40.00)       | 15 (60.00)  | 25 (11.74)     |
| SBP (mmHg)                  |                  |             |                |
| <140                        | 102 (52.04)      | 94 (47.96)  | 196 (92.02)    |
| ≥140                        | 11 (64.71)       | 6 (35.29)   | 17 (7.98)      |
| DBP (mmHg)                  |                  |             |                |
| <90                         | 99 (51.83)       | 92 (48.17)  | 191 (89.67)    |
| ≥90                         | 14 (63.64)       | 8 (36.36)   | 22 (10.33)     |
| Clinical characteristics    |                  |             |                |
| FPG (mmol/L)                |                  |             |                |
| <7.0                        | 41 (95.35)       | 2 (4.65)    | 43 (20.19)     |
| ≥7.0                        | 72 (42.35)       | 98 (57.65)  | 170 (79.81)    |
| HbA1c (%)                   |                  |             |                |
| <7                          | 34 (87.18)       | 5 (12.82)   | 39 (18.32)     |
| ≥7                          | 79 (45.40)       | 95 (54.60)  | 174 (81.69)    |
| FIns (mU/L)                 |                  |             |                |
| <5                          | 11 (78.57)       | 3 (21.43)   | 14 (6.57)      |
| 5 < 20                      | 98 (50.78)       | 95 (49.22)  | 193 (90.61)    |
| ≥20                         | 4 (66.67)        | 2 (33.33)   | 6 (2.82)       |
| HOMA-IR                     |                  |             |                |
| <2.8                        | 33 (80.49)       | 8 (19.51)   | 41 (19.25)     |
| ≥2.8                        | 80 (46.51)       | 92 (53.49)  | 172 (80.75)    |
| TG (mmol/L)                 |                  |             |                |
| <1.7                        | 48 (66.67)       | 24 (33.33)  | 72 (33.80)     |
| ≥1.7                        | 65 (46.10)       | 76 (53.90)  | 141 (66.20)    |
| TC (mmol/L)                 |                  |             |                |
| <5.2                        | 69 (53.91)       | 59 (46.09)  | 128 (60.09)    |
| ≥5.2                        | 44 (51.76)       | 41 (48.24)  | 85 (39.91)     |
| HDL-C (mmol/L)              |                  |             |                |
| >1.0                        | 45 (50.56)       | 44 (49.44)  | 89 (41.78)     |
| ≤1.0                        | 68 (54.84)       | 56 (45.16)  | 124 (58.22)    |
| LDL-C (mmol/L)              |                  |             |                |
| <2.6                        | 42 (58.33)       | 30 (41.67)  | 72 (33.80)     |
| ≥2.6                        | 71 (50.35)       | 70 (49.65)  | 141 (66.20)    |
| VitD (ng/ml)                |                  |             |                |
| ≥30                         | 4 (80.00)        | 1 (20.00)   | 5 (2.35)       |
| 15 < 30                     | 81 (62.31)       | 49 (37.69)  | 130 (61.03)    |
| <15                         | 28 (55.90)       | 20 (44.10)  | 78 (36.62)     |

(Continued)
Currently, due to high sensitivity and specificity, fundus photography is routinely employed in clinical settings for DR screening (8, 14). Additionally, screening merely evaluates the outcomes and does not reveal the components that play a part in creating the impact. DR is known to be one of the long-term effects of T2DM. It is widely accepted that diabetes is a potential risk for DR; nonetheless, it is unclear whether other factors lead to the development of DR. What is the significance of the relationship between DR and factors? Interestingly, nomograms can provide answers to all of these questions.

According to studies such as the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS), overweight, disease duration, hypoglycemia, hypertension, high cholesterol, kidney disease, renal failure (diabetic kidney disease (DKD)), pregnancy, and susceptibility genes are common triggers for DR (15, 16). In this study, gender, age, disease duration, SBP, DBP, BMI, FPG, HbA1c, TG, TC, HOMA-IR, LDL-C, HDL-C, VitD-T3, and Cr, which are clinically available clinical indicators, were correlated with the risk of DR using the LASSO method. Furthermore, multivariate logistic regression analysis identified disease duration, BMI, FPG, HbA1c, HOMA-IR, TG, TC, and VitD as risk factors for DR. Except for disease duration, all other risk factors are modifiable. In short, the value of our model is the identification and management of such modifiable risk factors.

Recently, hyperglycemia and disease duration have been identified as risk factors for the pathogenesis of DR (17, 18). Consistently, our prediction model suggests greater risk levels for high fasting glucose and disease progression. Moreover, DR is a metabolic disorder that is difficult to treat and does not develop in patients with reasonable glycemic control. In contrast, patients with poor glycemic control are more likely to develop DR, implying that there are additional secondary contributing factors. According to previous studies, the probability of developing DR increases by approximately 64% per 10% increase in HbA1c and the two have a positive relationship (19–22). Lower serum levels may decrease the risk of severe blindness by 47% when compared with normal serum

| Cr (µmol/L) | Non-DR (n = 113) | DR (n = 100) | Total (N = 213) |
|------------|-----------------|-------------|----------------|
| ≥90        | 104 (55.03)     | 85 (44.97)  | 189 (88.73)    |
| <90        | 9 (37.50)       | 15 (52.50)  | 24 (11.27)     |

BML, body mass index; Cr, creatinine; DBP, diastolic blood pressure; DR, diabetic retinopathy; FPG, fasting blood glucose; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment-insulin resistance; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; VitD, vitamin D.

**TABLE 1 Continued**

**FIGURE 1**
Least absolute shrinkage and selection operator (LASSO) logistic regression for assessing the relationship between populations and clinical features. (A) The optimum parameter in the LASSO regression model was chosen using a threshold of 16 cross-validations. The partial probability variance curves and the logarithm turn are shown. To get the best estimate, we used the 1-SE technique with minimum standards. (B) For each of the 16 characteristics, the LASSO logistic regression coefficients were calculated. The logarithmic lambda was used to determine the profile. The ideal lambda was tested using a cross-validation technique, with the optimal lambda producing eight coefficients.
FIGURE 2
The forest plot of the odds ratio (OR) of the Cox regression results.

FIGURE 3
Diabetic retinopathy (DR) nomogram. The graph was created using data from the following sources: disease duration, body mass index (BMI), fasting blood glucose (FPG), glycated hemoglobin (HbA1c), homeostatic model assessment-insulin resistance (HOMA-IR), triglyceride (TG), total cholesterol (TC), and vitamin D (VitD)-T3.
levels after approximately 20 years of follow-up (23). In addition, lipotoxicity, damage to the retinal barrier caused by excessive blood lipids, and exceptionally high TGs are a vital part of DR (24, 25). Thus, controlling dyslipidemia in addition to glycemic management is critical for preventing and treating DR (26).

According to the independent variables assessed in our prediction model, HbA1c and lipids could be risk factors for DR. Thus, lowering blood glucose and controlling lipids are among the most critical preventive and therapeutic strategies for DR.

Although nomogram models have been used earlier to predict the risk of DR (6), our model yielded a higher C-index...
value, indicating a higher accuracy. The indicators included in our model are more comprehensive than those included in the previous models, making it a more accurate predictor of risk. This study included popular Vitamin D (VD) from recent years that other researchers have not used. Low levels of VD are a specific and sensitive sign of proliferative diseases. Additionally, they are adversely associated with the intensity of DR. The AUC recommends VD as a straightforward, sensitive, and specific laboratory test for DR (27). According to a foreign cross-sectional investigation, patients with VD insufficiency were more likely to acquire DR than those with VD sufficiency. Multidisciplinary ordinal regression analysis revealed a link between VD shortage and DR severity (28–30). Consistently, this study identified VD rates as a predictor of DR, and the incidence of DR increases with decreasing VD levels. Relevant mechanisms have been proposed for determining the role of VD in DR, including VD increasing endothelial nitric oxide synthase (eNOS)-dependent NO production, reducing oxidative stress, and enhancing pathophysiological processes, such as vascular endothelial growth factor (VEGF) synthesis and release (31–33). However, according to a prospective observational study, VD deficit is directly linked to all-cause survival and does not predict the development of microvascular complications (34).

Inevitably, there are certain flaws in this research. Firstly, the sample size was small. Secondly, although it was a long-term assessment to evaluate the risk of DR, the study did not account for the bias caused by patients’ medications as DR progressed. Thirdly, because lighting affects VitD-T3, we could not collect data from patients during a continuous daytime period. As previously said, the risk or the occurrence of DR is not uniform; hence, we need to incorporate more indicators to derive more preventive methods for DR in patients with T2DM.

**Conclusion**

This study successfully constructed a nomogram for assessing the risk of DR in patients with T2DM. These findings will guide patients and doctors to develop personalized treatment plans based on these risk factors, eliminate the hazard of DR, and avoid the onset and development of DR.

**Data availability statement**

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.
Ethics statement

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

QW, NZ, and HT contributed to the conception and design of the study. QW, NZ, XY, QY, LZ, HZ, YZ, XN, and FJ contributed to data collection, analysis, and interpretation. QW and NZ wrote the article. XL and FJ revised the manuscript. The final article was read and approved by all participants before submission. QW and NZ contributed equally to this work.

Funding

Thanks to our colleagues at Zunyi Medical College’s Affiliated Hospital for helping us with data collection. This research was funded in part by the Chinese National Science Foundation (82060273) and the Guizhout Technology and Science Program [Qian Ke He Base -ZK (2021) - General 407]. The article’s completion is entirely at the discretion of the funders.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American diabetes association: National cross sectional study. BMJ (2020) 369:m9997. doi: 10.1136/bmj.m9997

2. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the international diabetes federation diabetes atlas, 9(th) edition. Diabetes Res Clin Pract (2019) 157:107843. doi: 10.1016/j.diabres.2019.107843

3. Jenkins AJ, Joglekar MV, Hardikar AA, Keech AC, O’Neal DN, Janszewska AS, et al. Biomarkers in diabetic retinopathy. Rev Diabet Stud (2015) 12(1-2):159-95. doi: 10.19080/RDS.2015.12.159

4. Shi R, Niu Z, Wu R, Zhang T, Cai D, Sun H, et al. Nomogram for the risk of diabetic nephropathy or diabetic retinopathy among patients with type 2 diabetes mellitus based on questionnaire and biochemical indicators: A cross-sectional study. Diabetes Metab Syndr Obes (2020) 13:1215–29. doi: 10.2147/DMSO.S244061

5. Li Y, Li C, Zhao S, Yin Y, Zhang X, Wang K, et al. Nomogram for prediction of diabetic retinopathy among type 2 diabetes population in xinjiang, China. Diabetes Metab Syndr Obes (2022) 15:1077–89. doi: 10.2147/DMSO.S354541

6. Mo R, Shi R, Hu Y, Hu F. Nomogram-based prediction of the risk of diabetic retinopathy: A retrospective study. J Diabetes Res (2020) 2020:2961047. doi: 10.1155/2020/2961047

7. Alberti KG, Zimet PT. Definition, diagnosis and classification of diabetes mellitus and its complications: part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med (1998) 15(7):539–53. doi: 10.1002/(SICI)1096-9166(199807)15:7<539::AID-DIA668>3.0.CO;2-S

8. Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, Vanderleeuk BL, et al. Diabetic retinopathy: A position statement by the American diabetes association. Diabetes Care (2017) 40(3):412–8. doi: 10.2337/dc16-2641

9. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol (2015) 16(4):e173–80. doi: 10.1016/S1470-2045(14)71116-7

10. Jiang F, Wei K, Lyu W, Wu C. Predicting risk of insulin resistance in a Chinese population with polycystic ovary syndrome: Designing and testing a new predictive nomogram. BioMed Res Int (2020) 2020:8031497. doi: 10.1155/2020/8031497

11. Kramer AA, Zimmerman JE. Assessing the calibration of mortality benchmarks in critical care: The hosmer-lemeshow test revisited. Crit Care Med (2007) 35(9):2052–6. doi: 10.1097/01.CCM.0000275267.64078.B0

12. Vickers AJ, Cronin AM, Elkin EB, Gonen. M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak (2008) 8:53. doi: 10.1186/1472-6947-8-53

13. Zeng N, Li Y, Wang Q, Chen Y, Zhang Y, Zhang L, et al. Development and evaluation of a new predictive nomogram for predicting risk of herpes zoster infection in a Chinese population with type 2 diabetes mellitus. Risk Manag Healthc Policy (2021) 14:4789–97. doi: 10.2147/RMHP.S310938

14. Ahmed J, Ward TP, Bursell SE, Aiello LM, Cavallerano JD, Vigersky: RA, et al. The sensitivity and specificity of nonmydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy. Diabetes Care (2006) 29(10):2205–9. doi: 10.2337/dci06-0295

15. Song SJ, Wong TY. Current concepts in diabetic retinopathy. Diabetes Metab J (2014) 38(6):416–25. doi: 10.4093/dmj.2014.38.6.416

16. Kuo JZ, Wong TY, Rotton II. Challenges in elucidating the genetics of diabetic retinopathy. JAMA Ophthalmol (2014) 132(1):96–107. doi: 10.1001/ jamaophthalmol.2013.5024

17. Ting DS, Cheung GG, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol (2016) 44(4):260–77. doi: 10.1111/cio.12696

18. Tan GS, Ikram MK, Wong TY. Traditional and novel risk factors of diabetic retinopathy and research challenges. Curr Med Chem (2013) 20(26):3189–99. doi: 10.2174/092986713209990023

19. Wat N, Wong RL, Wong IY. Associations between diabetic retinopathy and systemic risk factors. Hong Kong Med J (2016) 22(6):589–99. doi: 10.12809/ hkmj164869

20. Almotairi NM, Alhamed S, Alharbi M, Gotah S, Alharbi: M. The association between HbA1c and other biomarkers with the prevalence and severity of diabetic retinopathy. Curr Eye Res (2021) 13(1):e12520. doi: 10.7759/ cureye.12520

21. Kim HU, Park SP, Kim YK. Long-term HbA1c variability and the development and progression of diabetic retinopathy in subjects with type 2 diabetes. Sci Rep (2021) 11(1):4731. doi: 10.1038/s41598-021-84150-8
22. Su JB, Zhao LH, Zhang XL, Cai HL, Huang HY, Xu F, et al. HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients. *Cardiovasc Diabetol* (2018) 17(1):47. doi: 10.1186/s12933-018-0693-0

23. Gong Q, Gregg EW, Wang J, An Y, Zhang P, Yang W, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China da Qing diabetes prevention outcome study. *Diabetologia* (2011) 54(2):300–7. doi: 10.1007/s00125-010-1948-9

24. Chait A, Goldberg I. Treatment of dyslipidemia in diabetes: Recent advances and remaining questions. *Curr Diabetes Rep* (2017) 17(11):112. doi: 10.1007/s11892-017-0942-8

25. Filippatos T, Tsimihodimos V, Pappa E, Elisaf M. Pathophysiology of diabetic dyslipidaemia. *Curr Pharmaceut* (2017) 15(6):566–75. doi: 10.2174/1570161115666170201105425

26. Guo F, Zhou T, Tang J, Dong M, Wei Q. Related risk factors between subclinical carotid atherosclerosis and diabetic retinopathy in newly diagnosed type 2 diabetes mellitus in China. *Exp Clin Endocrinol Diabetes* (2021) 129(4):283–8. doi: 10.1055/a-0865-1754

27. Nadri G, Saxena S, Mahdi AA, Kaur A, Ahmad MK, Garg P, et al. Serum vitamin d is a bimolecular biomarker for proliferative diabetic retinopathy. *Int J Retina Vitreous* (2019) 5:31. doi: 10.1186/s40942-019-0181-x

28. Long M, Wang C, Liu D. Glycated hemoglobin A1C and vitamin d and their association with diabetic retinopathy severity. *Nutr Diabetes* (2017) 7(6):e281. doi: 10.1038/nutd.2017.30

29. Sari A, Akdogan AZ, Arifoglu KC, Bilir KB, Durmus, B, et al. Does vitamin d affect diabetic neuropathic pain and balance? *J Pain Res* (2020) 13:171–9. doi: 10.2147/JPR.S203176

30. Hu X, Liu W, Yan Y, Liu H, Huang Q, Xiao Y, et al. Vitamin d protects against diabetic nephropathy: Evidence-based effectiveness and mechanism. *Eur J Pharmacol* (2019) 845:91–8. doi: 10.1016/j.ejphar.2018.09.037

31. Opatrilova R, Kubatka P, Caperada M, Buselberg D, Kraunik V, Vesely P, et al. Nitric oxide in the pathophysiology of retinopathy: evidences from preclinical and clinical researches. *Acta Ophthalmol* (2018) 96(3):222–31. doi: 10.1111/aos.13884

32. Tecilazich F, Formenti AM, Giustina A. Role of vitamin d in diabetic retinopathy: Pathophysiological and clinical aspects. *Rev Endocr Metab Disord* (2021) 22(4):715–27. doi: 10.1007/s11154-020-09575-4

33. Azhan A, Zunaina E, Mahaneem M, Siti-Azrin AH. Comparison of VEGF level in tears post phacoemulsiﬁcation between non-proliferative diabetic retinopathy and non-diabetic patients. *J Diabetes Metab Disord* (2021) 20(2):2073–9. doi: 10.1007/s40200-021-00875-3

34. Joergensen C, Hovind P, Schmedes A, Parving HH, Rossing. P. Vitamin d levels, microvascular complications, and mortality in type 1 diabetes. *Diabetes Care* (2011) 34(5):1081–5. doi: 10.2337/dc10-2459